Decode Age, a Bengaluru-based longevity science startup, has raised ₹14.48 crore in its pre-Series A funding round led by Dr Krishna Prasad Chigurupati (Chairman and Managing Director, Granules India).
The fresh funds raised will be used to expand its biomarker discovery programmes, advance its multi-omics and microbiome research pipeline and enhance scientific and analytical infrastructure. It will also support formulation research aligned with key hallmarks of ageing, including areas such as cellular energy, metabolic balance, inflammatory pathways and cognitive resilience, as well as deeper collaboration across the longevity ecosystem.
Founded in 2021 by Parth Amin, Darshit Patel, and Rakesh Somani, Decode Age is a longevity science organisation focused on ageing biology, biomarker research and gut microbiome science. Decode Age has built a comprehensive longevity research platform that spans multi-omics testing, biomarker discovery and precision-based interventions.
At the heart of this ecosystem is a whole genome gut microbiome analysis system, providing high-resolution insights into microbial diversity and its influence on immunity, metabolism and ageing pathways. Its laboratory workflows prioritise precision and reproducibility, supporting researchers, clinicians and individuals who seek deeper biological understanding and practical tools for healthy ageing.
The company is using these insights to develop a new generation of research-driven supplements and longevity solutions that are informed by ageing biology and microbiome data. The focus is on supporting healthy ageing and biological pathways that sit behind age-related conditions such as cancer, dementia and other chronic diseases, in line with prevailing scientific evidence and regulatory standards.
The company aims to position India as a leader in microbiome science and healthy ageing research, and to create solutions that meet international standards of scientific rigour, quality and translational value.
Decode Age has collaborated with the Indian Institute of Science and global longevity initiatives like XPRIZE through a partnership, where it supports microbiome-linked data generation, analysis and longevity medicines.
Since its inception in 2021, the company has established advanced metagenomics and microbiome laboratories, introduced whole genome microbiome analysis for individuals and developed precision-designed formulations informed by ageing biology and microbiome science.
Parth Amin, CEO and Co-founder, Decode Age, said, “This investment marks an important step forward in our mission to bring scientific precision to the way people understand their biology. The support from Dr Chigurupati strengthens our ability to advance ageing and gut microbiome research, expand our biomarker programmes and build the scientific infrastructure that drives our work. We are grateful for his belief in our vision and remain committed to translating rigorous science into insights that help individuals make informed decisions about their long-term health.”
Dr Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India, said, “Decode Age is advancing an area of science that will redefine how we think about health, disease and ageing. Their capabilities in gut microbiome research and ageing biology are rigorous and forward-looking, offering individuals and clinicians biological insights that were previously inaccessible. This investment reflects my confidence in their scientific vision and the long-term impact they aim to create.”
